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Introduction
Membrane-anchored RING-CH1 (MAR CH1) is a mem-
brane-anchored ubiquitin ligase expressed in hematopoietic 
cells, particularly antigen presenting cells (Matsuki et al., 2007). 
It is composed of an N-terminal cytoplasmic tail that possesses 
a catalytic RING domain, two transmembrane domains that in-
teract with a specific substrate, and a C-terminal cytoplasmic 
tail. Upon recognition of substrate, MAR CH1 brings a ubiquiti-
nated E2 ubiquitin-conjugating enzyme into close proximity of 
its RING domain and substrate and catalyzes ubiquitin transfer 
from E2 to substrate. Transferred ubiquitin molecules serve as 
a signaling motif for endocytosis and lysosomal sorting, result-
ing in internalization and lysosomal degradation of the substrate 
(Lehner et al., 2005; Ohmura-Hoshino et al., 2006).
Several immune-associated molecules have been shown 
to be endocytosed and degraded in cells overexpressing MAR 
CH1 (Bartee et al., 2004). However, major histocompatibility 
complex II (MHC II) and CD86 are the only molecules shown 
to be ubiquitinated by MAR CH1 under physiological condi-
tions (Matsuki et al., 2007; De Gassart et al., 2008; Baravalle 
et al., 2011). MHC II has an evolutionally conserved lysine in 
the cytoplasmic tail in its β-chain, and this lysine is targeted for 
ubiquitination (Shin et al., 2006; van Niel et al., 2006; Oh and 
Shin, 2015). CD86 has multiple lysines in the cytoplasmic tails, 
and many of these lysines can be ubiquitinated (Baravalle et 
al., 2011; Corcoran et al., 2011). In accordance with the role of 
MAR CH1 in mediating ubiquitination and endocytosis of MHC 
II and CD86, MAR CH1 ablation resulted in a marked increase 
in the surface expression of these two molecules in dendritic 
cells (DCs) in mice. Interestingly, these mice exhibited a sig-
nificant reduction in the number of regulatory T (Treg) cells 
in the thymus (Oh et al., 2013). More interestingly, mice defi-
cient in the cytoplasmic lysine (K) of MHC II (called “MHC II 
K” here) exhibited a similar deficiency in thymic Treg cells (Oh 
et al., 2013). Furthermore, DCs deficient in MAR CH1 or MHC 
II K were defective at differentiating immature thymocytes to 
Treg cells in vitro (Oh et al., 2013). This finding suggests that 
MHC II ubiquitination plays an important role in DC function 
of selecting Treg cells. However, the underlying mechanisms 
have not been identified.
Treg cells are selected through a cognate interaction of 
CD4+ thymocytes with thymic antigen-presenting cells, and the 
strength of this interaction is one of the key determinants for 
Treg cell selection (Hsieh et al., 2012; Stritesky et al., 2012; 
Klein et al., 2014). Low-avidity interaction does not relay suffi-
cient signal to interacting thymocytes for expression of foxp3, 
the key transcription factor that guides Treg cell differentiation, 
whereas high-avidity interaction triggers apoptotic cell death 
resulting in negative selection of the interacting thymocytes. 
Dendritic cells (DCs) produce major histocompatibility complex II (MHC II) in large amounts to function as professional 
antigen presenting cells. Paradoxically, DCs also ubiquitinate and degrade MHC II in a constitutive manner. Mice defi-
cient in the MHC II-ubiquitinating enzyme membrane-anchored RING-CH1, or the ubiquitin-acceptor lysine of MHC II, 
exhibit a substantial reduction in the number of regulatory T (Treg) cells, but the underlying mechanism was unclear. Here 
we report that ubiquitin-dependent MHC II turnover is critical to maintain homeostasis of lipid rafts and the tetraspanin 
web in DCs. Lack of MHC II ubiquitination results in the accumulation of excessive quantities of MHC II in the plasma 
membrane, and the resulting disruption to lipid rafts and the tetraspanin web leads to significant impairment in the 
ability of DCs to engage and activate thymocytes for Treg cell differentiation. Thus, ubiquitin-dependent MHC II turnover 
represents a novel quality-control mechanism by which DCs maintain homeostasis of membrane domains that support 
DC’s Treg cell–selecting function.
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Only the intermediate-avidity interaction delivers a signal ap-
propriate for Treg cell differentiation.
DCs deficient in MAR CH1 or the MHC II K display 
peptide-loaded MHC II (pMHC II) at much larger amounts than 
WT DCs on the surface (Walseng et al., 2010; Oh et al., 2013). 
Because pMHC II is the molecule that mediates a cognate inter-
action of DCs with CD4+ thymocytes, an increase in pMHC II in 
DCs will increase DC avidity for antigen-specific thymocytes. 
The increased avidity is then likely to drive the thymocytes to 
apoptotic cell death while repressing differentiation into Treg 
cells. However, the mice deficient in MAR CH1 or MHC II K did 
not show any increase in apoptotic cell death of CD4+ thymo-
cytes or Treg cells (Oh et al., 2013). Furthermore, lowering the 
amount of the peptide loaded onto MHC II did not restore the 
development of Treg cells in MAR CH1 or MHC II K–deficient 
mice (Oh et al., 2013). This finding suggests that the role of 
MAR CH1 in supporting DC function of selecting Treg cells 
is independent of controlling surface expression of pMHC II. 
In this study, we have investigated the specific mechanism by 
which MAR CH1-dependent MHC II ubiquitination supports 
DC selection of Treg cells.
Results
DC expression of MAR CH1 is important 
for Treg cell development in the thymus
To determine the extent to which DCs contribute to the role 
of MAR CH1 in promoting Treg cell development in vivo, we 
generated mice with loxP-flanked alleles of the RING do-
main of MAR CH1 and bred them to CD11c-CRE transgenic 
mice expressing CRE recombinase under the control of the 
CD11c promoter (MAR CH1fl/fl CD11c-CRE mice, Fig. S1). 
The loxP-flanked region of MAR CH1 was efficiently and 
specifically deleted in DCs of MAR CH1fl/flCD11c-CRE mice 
(Fig. 1 A). DCs in these mice expressed MHC II at markedly 
elevated levels, similar to DCs from MAR CH1-deficient mice 
(MAR CH1−/−) or MHC II K–deficient mice (MHC IIK>R/K>R, the 
mice in which the ubiquitin acceptor lysine K of MHC II was 
replaced with arginine [R]; Fig. 1 B). MAR CH1fl/flCD11c-CRE 
mice had a normal number of total, CD4−CD8−, CD4+CD8+, 
CD4+CD8−, and CD4−CD8+ thymocytes, but the number of 
Treg cells was reduced by approximately half (Fig. 1 C), simi-
larly to what has been observed in MAR CH1−/− mice and MHC 
IIK>R/K>R mice (Oh et al., 2013). Thus, the role of MAR CH1 
in promoting Treg cell development is critically dependent on 
MAR CH1 expressed in DCs.
MAR CH1-mediated MHC II ubiquitination is 
required for DCs to effectively engage and 
activate thymocytes
We have previously shown that DCs deficient in MAR CH1 
were poor at differentiating immature thymocytes into Treg 
cells in vitro. To determine how MAR CH1 deficiency impairs 
DC function of developing Treg cells, we examined whether 
MAR CH1 is important for DCs to stably engage thymocytes 
and provide sufficient stimulatory signal for activation. DCs 
were isolated from thymi of MAR CH1-deficient mice, loaded 
with ovalbumin, and co-cultured with CD4+ thymocytes iso-
lated from the mice expressing ovalbumin-specific T cell recep-
tor (TCR; OT-II mice). 3 h later, the number of DCs that formed 
stable conjugate with thymocytes was determined by flow cy-
tometry. We found that MAR CH1-deficient DCs were engaged 
by thymocytes to a lower frequency than WT DCs (Fig. 2, A 
and B). 24 h later, we also determined the expression of CD69 
and CD25 in thymocytes, specific indicators of thymocyte acti-
vation involving early and late TCR signaling, respectively. We 
found that the thymocytes cultured with MAR CH1-deficient 
DCs expressed CD69 to a significantly lower frequency than 
those cultured with WT DCs (Fig. 2, C and D). The thymocytes 
that had been cultured with MAR CH1-deficient DCs and ex-
pressed CD69 were found to express lower levels of CD25 than 
those cultured with WT DCs. (Fig. 2, C and E). These findings 
indicate that MAR CH1 is required for DCs to stably engage 
thymocytes and provide them with strong and/or sustained 
signal for activation. It is noteworthy that MAR CH1-deficient 
Figure 1. DC expression of MAR CH1 is im-
portant for Treg cell development in the thy-
mus. (A) The amount of loxp-flanked MAR CH1 
genomic DNA (gDNA) in Sirpα− thymic DCs, 
Sirpα+ thymic DCs, thymic B cells, and thymic 
epithelial cells (TECs) in MAR CH1fl/fl CD11c-
CRE mice relative to MAR CH1fl/fl mice. Each 
cell type was isolated by FACS as described 
previously (Oh et al., 2013). Data are aver-
aged from three individual mice. (B) Surface 
expression of MHC II in Sirpα− and Sirpα+ 
thymic DCs of MAR CH1fl/fl, MAR CH1fl/fl 
CD11c-CRE, MAR CH1−/−, and MHC IIK>R/K>R 
mice. Data represent three independent exper-
iments. (C) Numbers of total, CD4−CD8− (DN), 
CD4+CD8+ (DP), CD4+CD8− (CD4SP), and 
CD4−CD8+ (CD8SP) thymocytes and Treg cells 
(CD4+CD8−Foxp3+CD25+) in MAR CH1fl/fl and 
MAR CH1fl/fl CD11c-CRE mice. Each circle 
represents an individual mouse. Error bars rep-
resent SEM. **, P < 0.01.
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DCs were not much different from DCs of WT mice for the 
level of expression of the costimulatory molecule CD80 and 
the adhesion molecule ICAM1 (Fig. S2 A).
Next, we examined whether the role of MAR CH1 in pro-
moting DC engagement and activation of thymocytes depends 
on its activity of mediating ubiquitination of MHC II. For this 
examination, DCs were isolated from thymi of MHC IIK>R/K>R 
mice and analyzed as described earlier. Similar to MAR CH1- 
deficient DCs, MHC II K–deficient DCs engaged and activated 
thymocytes less efficiently than WT DCs (Fig. 2, F–H). MHC 
II K–deficient DCs were not altered for the expression of CD86, 
CD80, and ICAM-1 compared with WT DCs (Fig. S2 B). This 
finding indicates that the effect of MAR CH1 in promoting DC 
engagement and activation of thymocytes is largely dependent 
on its ability to ubiquitinate MHC II.
The presence of too many MHC II molecules, 
not the absence of ubiquitinated MHC II,  
is responsible for poor engagement and 
activation of thymocytes by MHC II K–
deficient DCs
To identify the specific mechanism by which MHC II ubiquiti-
nation supports DC engagement and activation of thymocytes, 
we used bone marrow–derived DCs (BMDCs), which showed 
a similar dependence on MHC II ubiquitination to engage and 
activate thymocytes (Fig. 3, B–D). We first tested whether too-
high expression of MHC II or the absence of ubiquitinated MHC 
II is responsible for the poor engagement and activation of thy-
mocytes by MHC II K–deficient DCs. To reduce surface MHC 
II levels without introducing MHC II ubiquitination, we crossed 
MHC IIK>R/K>R mice to MHC II−/− mice and derived BMDCs from 
Figure 2. MAR CH1 or MHC II K–deficient DCs are incompetent to stably engage and sufficiently activate CD4+ thymocytes. (A–E) DCs were isolated from 
WT or MAR CH1−/− mouse thymi and co-cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of oval-
bumin. After 3 h, the percentage of DCs that formed a stable conjugate with thymocytes was determined by flow cytometry as described in Materials and 
methods. The representative contour plots are shown in A, and the quantitative summary is shown in B. After 24 h, the expression of CD69 and CD25 in 
thymocytes was determined by flow cytometry. The representative contour plots are shown in C. The percentages of thymocytes that expressed CD69 are 
shown in D, and the level of CD25 expressed in the CD69+ thymocytes (geometric mean fluorescence intensity [gMFI]) are shown in E. (F–H) DCs were 
isolated from WT or MHC IIK>R/K>R mouse thymi, co-cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations 
of ovalbumin, and examined as described in the previous section. The percentage of DCs that formed a stable conjugate with thymocytes is shown in F, the 
percentage of thymocytes that expressed CD69 is shown in G, and the level of CD25 expressed in CD69+ thymocytes is shown in H. Data points represent 
two to three independent experiments with duplicate or triplicate per condition. Error bars represent SEM. *, P < 0.05; **, P < 0.01.
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resulting MHC IIK>R/− mice. These BMDCs expressed MHC II at 
slightly lower levels than BMDCs from MHC IIK>R/K>R mice on 
the surface (Fig. 3 A). Interestingly, these DCs engaged thymo-
cytes significantly better than DCs derived from MHC IIK>R/K>R 
mice, suggesting that too-high MHC II, not the absence of ubiq-
uitinated MHC II, exerted a negative impact on the ability of 
DCs to engage thymocytes (Fig. 3 B). DCs derived from MHC 
IIK>R/− mice also activated thymocytes more effectively than 
DCs derived from MHC IIK>R/K>R mice, although the degree of 
improvement was marginal (Fig. 3, C and D).
To further reduce surface MHC II levels in DCs, we ex-
pressed in DCs MHC II WT and MHC II (K>R) mutants using 
an exogenous promoter. BMDCs were cultured from MHC 
II−/− mice and transduced with the retrovirus encoding MHC 
II WT or MHC II (K>R) mutant (Shin et al., 2006). The retro-
virus encoding MHC II WT successfully drove the expression 
of MHC II in DCs (Fig. 3 E), but the level was low as ∼3% of 
the level expressed by the endogenous promoter (Fig. 3 F). 
DCs transduced with the retrovirus encoding MHC II (K>R) 
mutant expressed much higher levels of MHC II than DCs 
transduced with the retrovirus encoding MHC II WT but did 
not reach to the level expressed by DCs derived from WT 
mice (Fig.  3 F). Remarkably, we found that the DCs trans-
duced with the retrovirus encoding MHC II (K>R) mutant 
were superior to DCs transduced with the retrovirus encoding 
MHC II WT both at engaging and at activating thymocytes 
Figure 3. The presence of too many MHC II molecules, not the absence of ubiquitinated MHC II, is responsible for poor engagement and activation of thy-
mocytes by MHC II K-deficient DCs. (A–D) BMDCs were derived from WT, MHC IIK>R/K>R, and MHC IIK>R/− mice. The surface expression of MHC II is shown in 
A. The BMDC was cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. The 
percentage of DCs that formed stable conjugates with thymocytes is shown in B. The percentage of thymocytes that expressed CD69 is shown in C. The 
level of CD25 expressed in CD69+ thymocytes is shown in D. (E and F) BMDCs were derived from MHC IIβ−/− mice and transduced with retrovirus encod-
ing MHC IIβ WT or MHC IIβ (K>R) mutant along with cytosolic GFP. The efficiency of transduction and the expression of MHC II in transduced cells were 
determined by flow cytometry. The representative dot plots are shown in E (cells transduced with retrovirus encoding MHC II WT and MHC II [K>R] mutant 
are shown in left and right, respectively). The expression level of GFP and MHC II in transduced cells is shown in F (left and right panel, respectively). The 
level of MHC II expressed in DCs derived from WT mice was overlaid for comparison (blue in the right panel of F). The MFI of the MHC II stain in DCs 
transduced with retrovirus encoding MHC II WT and DCs derived from WT mice is indicated in F. (G–I) BMDCs were derived from MHC IIβ−/− mice and 
transduced with retrovirus encoding MHC IIβ WT or MHC IIβ (K>R) mutant along with cytosolic GFP. Transduced cells (GFP+ cells) were isolated by FACS 
and cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. The percentage of 
DCs that formed stable conjugates with thymocytes is shown in G. The percentage of thymocytes that expressed CD69 is shown in H. The level of CD25 
expressed in CD69+ thymocytes is shown in I. Data represent at least three independent experiments with triplicates for each condition. Error bars represent 
SEM. *, P < 0.05; **, P < 0.01.
role of mAr CH1 in plasma membrane homeostasis • oh et al. 1399
(Fig. 3, G–I). This finding provides definitive evidence that 
the failure of MHC II K–deficient DCs to effectively engage 
and activate thymocytes was because of the presence of too 
many MHC II molecules and not the absence of ubiquiti-
nated MHC II in the cells.
MHC II K deficiency alters the lipid raft 
and tetraspanin web in the plasma 
membrane of DCs
We sought to identify the specific mechanism by which too 
many MHC II molecules impair DC ability to engage and ac-
tivate thymocytes. MHC II is not randomly scattered in the 
plasma membrane of DCs but is associated with a distinct 
membrane domain named lipid raft, an ordered membrane 
structure composed of discrete species of lipids, including 
cholesterol, sphingolipid, and glycolipid (Anderson et al., 
2000; Anderson and Roche, 2015). The lipid raft also encom-
passes a specific set of proteins including glycosylphosphati-
dylinositol (GPI)-anchored molecules (Simons and Sampaio, 
2011). Although the mechanism by which MHC II associates 
with the lipid raft is not clearly understood, this association in-
creases the local concentration of MHC II loaded with antigens 
lowering the threshold of antigen-specific T cell activation 
(Anderson et al., 2000). We found that MHC II in MHC II K–
deficient DCs was fractionated into the light-buoyant den-
sity fractions at degrees similar to MHC II in WT DCs (Fig. 
S3), indicating that ubiquitination is not required for MHC 
II to associate with the lipid raft. However, we noticed that 
the absolute amount of MHC II associated with the lipid raft 
was markedly high in MHC II K–deficient DCs, although the 
amount associated with nonlipid raft was also high (Fig. S3). 
Because the lipid raft is an ordered structure made by tight 
interactions between lipids and proteins, we speculated that 
excessive accumulation of MHC II in the lipid raft might have 
altered the integrity of the structure, which in turn negatively 
affected the ability of MHC II K–deficient DCs to engage and 
activate thymocytes. Interestingly, we found that the antibod-
ies raised against the GPI-anchored molecule CD48 or CD24 
poorly bound to MHC II K–deficient DCs compared with WT 
DCs (Fig.  4  A). Cholera toxin B (CTxB), a specific ligand 
of the sphingolipid GM1, also poorly bound to MHC II K– 
deficient DCs (Fig.  4  A). However, the antibodies raised 
against the nonraft molecules CD45 and CD71 bound to MHC 
II K–deficient DCs similarly to WT DCs (Fig. 4 A).
In addition to the lipid raft, another membrane domain 
named tetraspanin web associates MHC II in DCs (Kropshofer 
Figure 4. MHC II K deficiency causes DCs to 
be poorly bound by antibodies or ligand di-
rected to the molecules associated with the 
lipid raft and tetraspanin web. (A and B) 
BMDCs derived from WT or MHC IIK>R/K>R mice 
were stained by using monoclonal antibodies 
raised against indicated molecules except that 
CTxB was used to detect GM1. Note that two 
monoclonal antibodies (MZ3 and KMC8) were 
used for CD9. Isotype control antibodies or 
unstained cells (for CTxB) were used as back-
ground (gray). Sirpα− DCs are shown as the 
representative of BMDCs. (C and D) BMDCs 
derived from WT or MHC IIK>R/K>R mice were 
fixed with paraformaldehyde. Some were sub-
sequently permeabilized and some were not 
before staining with antibodies or CTxB as 
described in A and B. Sirpα− DCs are shown 
as the representative. (E) BMDCs derived from 
WT or MHC IIK>R/K>R mice were lysed with 
TRIzol, and the amount of mRNA of indicated 
molecules was determined by quantitative RT-
PCR. Data were normalized to mRNA of HPRT. 
Error bars represent SEM. (F) BMDCs derived 
from WT or MHC IIK>R/K>R mice were run on 
SDS-PAGE and probed by using antibodies 
raised against indicated molecules. Data rep-
resent two to four independent experiments.
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et al., 2002; Unternaehrer et al., 2007). This membrane do-
main consists of tetraspanin molecules and a limited number 
of partner proteins and is enriched with cholesterol and the 
sphingolipid ganglioside similarly to the lipid raft (Charrin et 
al., 2014). We found that the antibodies raised against the tet-
raspanin molecule CD9 or CD81 also poorly bound to MHC II 
K–deficient DCs compared with WT DCs (Fig. 4 B). Antibod-
ies raised against CD63, CD37, or CD54 did not bind to either 
WT or MHC II K–deficient DCs possibly by little expression of 
these tetraspanins in the DC surface (unpublished data). These 
findings suggest that MHC II K deficiency induces substantial 
alteration in the composition or structure of the lipid raft and 
tetraspanin web in DC plasma membrane.
To better characterize alteration of the lipid raft and tetra-
spanin web in MHC II K–deficient DCs, we examined whether 
the alteration was restricted to the plasma membrane or also 
made in the intracellular compartments. First, we examined 
whether the aforementioned antibodies or CTxB bind more 
poorly to MHC II K–deficient DCs than WT DCs after fixa-
tion. As shown in Fig.  4  C.  the antibodies and CTxB poorly 
bound to fixed MHC II (K>R) DCs compared with fixed WT 
DCs. Then, we permeabilized the fixed DCs and stained them 
with the antibodies and CTxB. Permeabilization substantially 
increased the binding of anti-CD48 antibody, anti-CD24 anti-
body, and CTxB, implicating the presence of these molecules 
in intracellular compartments (Fig. 4 C). Notably, we found that 
permeabilization markedly reduced the difference in binding of 
the antibodies or CTxB between MHC II K–deficient DCs and 
WT DCs (Fig. 4 C), suggesting that the lipid raft in the intracel-
lular compartments of MHC II K–deficient DCs is not altered as 
much as that in the plasma membrane.
CD9 appeared mostly localized in the plasma membrane 
in DCs because permeabilization increased anti-CD9 anti-
body binding only to a marginal level (Fig. 4 C). The differ-
ence in binding of anti-CD9 antibody between WT and MHC 
II K–deficient DCs did not look much different after perme-
abilization. Binding of anti-CD81 antibody was substantially 
increased after permeabilization, implicating the presence of 
a substantial amount of intracellular CD81 (Fig.  4  D). The 
degree of binding difference between WT and MHC II K–de-
ficient DCs also increased after permeabilization indicating 
that there might be substantial alteration in CD81-associating 
tetraspanin web in the intracellular compartments of MHC II 
K-deficient DCs (Fig. 4 D).
Next, we examined whether MHC II K–deficient DCs ex-
pressed lipid raft or tetraspanin molecules at lower levels than 
WT DCs. First, we determined the level of mRNA by quanti-
tative RT-PCR. We did not find any significant reduction in the 
amount of transcript of CD48, CD24, CD9, or Sptlc2, the key 
enzyme in sphingolipid biosynthesis, in MHC II K–deficient 
DCs compared with WT DCs (Fig. 4 E). Second, we examined 
the protein amount by Western blot analysis. No difference was 
observed in the amount of CD48, CD9, or CD81, although the 
amount of CD24 appeared slightly lower in MHC II K–deficient 
DCs (Fig. 4 F). Thus, MHC II K–deficient DCs express CD48, 
CD9, and CD81 at levels similar to WT DCs whereas CD24 
might be expressed at slightly lower levels. Collectively, we 
conclude that that MHC II K deficiency in DCs is accompanied 
by substantial changes in the conformation and stability of the 
molecules associated with the lipid raft and tetraspanin web 
in the plasma membrane.
MHC II overcrowding is responsible for the 
alteration of the lipid raft and tetraspanin 
web in MHC II K–deficient DCs
Next, we determined whether the alteration of the lipid raft and 
tetraspanin web in MHC II K–deficient DCs was caused by MHC 
II overcrowding. DCs were cultured from MHC IIK>R/− mice and 
examined whether these DCs are better bound by anti-CD48, 
-CD24, or -CD9 antibodies and CTxB than DCs derived from 
MHC IIK>R/K>R mice. We found that all of these antibodies and 
CTxB bound better to DCs derived from MHC IIK>R/− mice 
(Fig. 5 A). We also examined binding of these antibodies and 
CTxB to DCs that expressed the MHC II (K>R) mutant and WT 
under the retroviral promoter described in Fig. 3. All the anti-
bodies and CTxB bound to DCs that expressed MHC II WT or 
the MHC II (K>R) mutant at similar levels (Fig.  5  B). These 
findings strongly support the hypothesis MHC II overcrowding 
is responsible for the alteration of the lipid raft and tetraspanin 
web in MHC II K–deficient DCs.
To further confirm that the alteration of the lipid raft and 
tetraspanin web in MHC II K–deficient DCs is attributed directly 
to MHC II overcrowding, we ablated MHC II ubiquitination in 
DCs in an inducible manner. The MAR CH1fl/fl mice described 
in Fig. 1 were crossed with ERT-Cre mice, which expressed es-
trogen receptor–Cre fusion protein under the human ubiquitin 
promoter. BMDCs were cultured from these mice and treated 
with the ligand of the estrogen receptor tamoxifen. Tamoxifen 
was expected to enter DCs and trigger cre-dependent recombi-
nation of the MAR CH1 gene. We found that tamoxifen treat-
ment resulted in an increase in the surface level of MHC II in 
as early as 24 h (Fig. 5 C). Importantly, this increase was ac-
companied by a reduction in the binding of anti-CD48, -CD24, 
or -CD9 antibodies but not CTxB (Fig.  5  C). On day 3 to 5 
after tamoxifen treatment, the level of surface MHC II further 
increased whereas the binding of anti-CD48, -CD24, or -CD9 
antibodies further decreased, and CTxB binding also decreased 
(Fig. 5 C). These data demonstrate a strong correlation between 
the degree of MHC II overcrowding and the degree of alter-
ation of the lipid raft and tetraspanin web, further supporting 
that MHC II overcrowding is the direct cause of alteration in 
these membrane domains. In addition, this finding suggests that 
GPI-anchored molecules and tetraspanin molecules are more 
readily altered than GM1 by MHC II overcrowding.
Because MAR CH1 ablation increases not only MHC II 
but also CD86, we tested whether CD86 accumulation may also 
induce similar alteration in the lipid raft and tetraspanin web. 
DCs derived from WT mice were transduced with the retrovi-
rus encoding CD86 (K>R) mutant in which the cytoplasmic 
lysines of CD86 were replaced with arginines (Baravalle et al., 
2011). We found that the cells transduced with this retrovirus 
expressed >50 times as many CD86 molecules as untransduced 
cells. However, the transduced and untransduced cells were 
bound by anti-CD24, -CD48, or -CD9 antibody and CTxB sim-
ilarly (Fig. S4), indicating that CD86 overcrowding does not 
make an alteration similar to what MHC II overcrowding makes.
Lipid raft and tetraspanin web support DC 
engagement and activation of thymocytes
We examined whether intact lipid raft or tetraspanin web is 
required for DCs to stably engage and sufficiently activate 
thymocytes. First, we disturbed the organization of these mem-
brane domains by using methyl β-cyclodextrin (MβCD), a 
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cholesterol-chelating agent (Charrin et al., 2003). MβCD treat-
ment diminished DC binding by anti-CD48, -CD24, or -CD9 
antibodies, and CTxB (Fig. 6 A), similarly to what MHC II K 
deficiency did. MβCD treatment also impaired DC ability to en-
gage and activate thymocytes (Fig. 6, B–D). Next, we treated 
BMDCs with myriocin, a potent and specific inhibitor of sptlc2 
(Hanada, 2003). Myriocin did not impair DC binding by anti- 
CD48 or -CD24 antibodies although it modestly impaired bind-
ing by CTxB and anti-CD9 or -CD81 antibodies (Fig.  6  E). 
Myriocin treatment significantly reduced the efficiency of DCs 
to engage and activate thymocytes (Fig. 6, F–H). Notably how-
ever, myriocin treatment markedly reduced the surface expres-
sion of MHC II in DCs (unpublished data). Because surface 
MHC II makes a direct impact on the efficiency of DC activa-
tion of antigen-specific thymocytes, it is unclear whether the 
reduced engagement and activation of thymocytes by myrio-
cin-treated DCs is the result of the perturbation of the lipid raft 
or tetraspanin web or the reduced surface expression of MHC II.
Then, we examined whether any specific molecules as-
sociated with the lipid raft or tetraspanin web are important for 
DCs to stably engage and sufficiently activate thymocytes. To 
this end, we pretreated DCs with anti-CD48, -CD24, -CD9, 
or -CD81 antibodies before culturing with OT-II thymocytes. 
We found that all of the antibodies appreciably reduced DC en-
gagement with thymocytes compared with the control antibody 
(anti-TNP), although the statistically significant difference was 
reached only by anti-CD48 antibody and the KMC8 anti-CD9 
antibody. (Fig.  6  I). These two antibodies also reduced DC 
engagement and activation of thymocytes at significant levels 
(Fig. 6, J and K). This finding implicates the role of CD48 and 
CD9 in DC engagement and activation of thymocytes and sug-
gests that alteration of these two molecules may be the primary 
cause for diminished engagement and activation of thymocytes 
by MHC II K–deficient DCs.
Sphingomyelin supplementation lessens the 
alteration of the lipid raft and tetraspanin 
web in MHC II K–deficient DCs and improves 
the ability of the DCs to engage and activate 
thymocytes and drive Treg cell differentiation
We sought to determine the specific mechanism by which MHC 
II overcrowding alters the lipid raft or tetraspanin web and deter-
mine whether this alteration is responsible for poor engagement 
and activation of thymocytes by MHC II K–deficient DCs. It has 
been suggested that MHC II binds cholesterol and sphingolipid 
through its transmembrane domain (Roy et al., 2013; Björkholm 
et al., 2014). We postulated that cholesterol and sphingolipid in 
the lipid raft and tetraspanin web may be sequestered by MHC II 
because MHC II accumulates in these membrane domains. This 
sequestration would make other molecules associated with the 
lipid raft or tetraspanin web deprived of cholesterol or sphingo-
lipid, resulting in alteration in the conformation or stability of 
the molecules. To test this hypothesis, we supplemented MHC 
II K–deficient DC culture with cholesterol or sphingomyelin 
and examined whether this supplementation makes the DCs 
better bound by anti-CD48, -CD24, -CD9, or -CD81 antibod-
ies or CTxB. We found that sphingomyelin significantly im-
proved DC binding by all these reagents (Fig.  7 A) although 
cholesterol did not (not depicted). Importantly, sphingomyelin 
also significantly improved the ability of MHC II K–deficient 
DCs to engage and activate thymocytes (Fig.  7, B–D). Then, 
we examined whether sphingomyelin treatment also improves 
Figure 5. MHC II overcrowding is responsible 
for alteration of the lipid raft and tetraspanin 
web in MHC II K–deficient DCs. (A) BMDCs 
derived from WT, MHC IIK>R/K>R, or MHC II 
K>R/- mice were stained by using monoclonal 
antibodies raised against indicated molecules 
except that CTxB was used to detect GM1. 
Sirpα− DCs are shown as the representative. 
(B) BMDCs derived from MHC IIβ−/− mice 
and subsequently transduced with retrovirus 
encoding MHC II WT or MHC II (K>R) mutant 
were treated and analyzed as described in 
A.  Sirpα− DCs are shown as the representa-
tive. (C) BMDCs cultured from MAR CH1fl/flERT-
Cre mice were treated with tamoxifen. On 
days 0, 1, 3, and 5 posttreatment, cells were 
stained with CTxB (to detect GM1) or anti-
bodies raised against CD48, CD24, CD9, 
or MHC II. Sirpα− DCs are shown as the 
representative. Data represent two to four 
independent experiments.
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the ability of MHC II K–deficient DCs to drive Treg cell de-
velopment. Immature non-Treg CD4+ thymocytes were isolated 
from FoxpGFPOT-II mice, which report Foxp3 by GFP expres-
sion. The isolated thymocytes were co-cultured with MHC II K–
deficient DCs that had been supplemented with sphingomyelin 
in the presence of increasing concentrations of ovalbumin pep-
tide. 2 d later, the expression of GFP and CD25 in thymocytes 
was determined by flow cytometry. We found that the thymo-
cytes cultured with sphingomyelin-treated DCs expressed GFP 
and CD25, the markers of Treg cells, at a significantly higher 
frequency than those cultured with vehicle-treated DCs (Fig. 7, 
E and F). Thus, sphingomyelin supplementation significantly 
restores the ability of MHC II K–deficient DCs to drive Treg 
cell development. Collectively, these findings suggest that the 
alteration of the lipid raft and tetraspanin web was responsible 
for poor engagement, activation, and Treg cell differentiation 
Figure 6. Lipid raft and tetraspanin web support DC engagement and activation of thymocytes. (A) BMDCs were treated with PBS or MβCD (4 mM) for 
3 h and stained by using monoclonal antibodies raised against indicated molecules except that CTxB was used to detect GM1. (B–D) BMDCs pretreated 
with PBS or MβCD were cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. 
The percentage of DCs that formed stable conjugates with thymocytes is shown in B. The percentage of thymocytes that expressed CD69 is shown in 
C. The level of CD25 expressed in CD69+ thymocytes is shown in D. (E) BMDCs were treated with methanol (MeOH) or myriocin (0.5 μg/ml) for 3 d and 
stained by using monoclonal antibodies raised against indicated molecules except that CTxB was used to detect GM1. (F–H) BMDCs treated with MeOH 
or myriocin were cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. The 
percentage of DCs that formed stable conjugates with thymocytes is shown in F. The percentage of thymocytes that expressed CD69 is shown in G. The 
level of CD25 expressed in CD69+ thymocytes is shown in H. (I–K) BMDCs were treated with indicated antibodies for 30 min at 37°C. After washing, the 
DCs were cultured with CD4+CD8− thymocytes isolated from OT-II mice in the presence of increasing concentrations of OVA323-339 peptide. The percentage 
of DCs that formed stable conjugates with thymocytes is shown in I. The percentage of thymocytes that expressed CD69 is shown in J. The level of CD25 
expressed in CD69+ thymocytes is shown in K. Statistical analysis was performed in comparison to the cells treated with anti-TNP antibody (control) in 
I–K. Data represent three to four independent experiments. Error bar represents SEM. *, P < 0.05; **, P < 0.01.
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of thymocytes by MHC II K–deficient DCs and suggest that 
sphingolipid may be one of the limiting factors in MHC II K–
deficient DCs for maintaining homeostasis of the lipid raft and 
tetraspanin web against MHC II overcrowding.
The degree of Treg cell deficiency in MAR 
CH1- or MHC II K–deficient mice correlates 
with the degree of alteration in the lipid 
raft and tetraspanin web in thymic DCs
The data described so far led to the hypothesis that the failure 
of MHC IIK>R/K>R or MAR CH1−/− mice to generate Treg cells to 
a sufficient number is attributed to the failure of thymic DCs 
of these mice to maintain homeostasis of the lipid raft and/or 
tetraspanin web. To test this hypothesis, we first examined thy-
mic DCs derived from WT, MHC IIK>R/K>R, and MHC IIK>R/− for 
binding by anti-CD48, -CD24, or -CD9 antibodies and CTxB. 
Similar to what was observed with BMDCs (Fig. 5 A), these 
antibodies and reagent bound to DCs derived from WT mice 
the most, and DCs derived from MHC IIK>R/K>R mice the least 
(Fig.  8  A). Then, we compared the ability of these mice to 
generate antigen-specific Treg cells. The generation of OVA- 
specific Treg cells was examined in conditions where OVA was 
expressed in the thymus under the control of a rat insulin pro-
moter (Fig. 8 B) or administered to the circulation (Fig. 8 C; 
Oh et al., 2013). Although MHC IIK>R/K>R mice completely failed 
to generate OVA-specific Treg cells in both conditions, MHC 
IIK>R/− mice generated them to an appreciable amount; however, 
it did not reach the amount generated by WT mice (Fig. 8, B and 
C). Lastly, we compared the amount of total Treg cells in WT, 
MHC IIK>R/K>R, and MHC IIK>R/− mice. Treg cell frequency was 
reduced by half in MHC IIK>R/K>R mice compared with WT mice, 
and it remained similarly low in MHC IIK>R/− mice (Fig. 8 D).
We performed similar experiments using MAR CH1−/− 
and MAR CH1−/+ mice. Thymic DCs of MAR CH1−/− mice were 
most poorly bound by anti-CD48, -CD24, or -CD9 antibodies 
and CTxB, and DCs of MAR CH1−/= mice showed markedly 
improved binding (Fig. 8 E). OVA-specific Treg cells were not 
generated at all in MAR CH1−/− mice but were generated in MAR 
CH1−/+ mice as efficiently as in WT mice both when OVA was 
expressed in the thymus and when administered to the circu-
lation (Fig. 8, F and G). The total Treg cell amount was also 
significantly restored in MAR CH1−/+ mice, although it did not 
reach the level of WT mice (Fig. 8 H). Collectively, Treg devel-
opment in the thymus decreased in proportion to the degree to 
Figure 7. Sphingomyelin supplementation lessens alteration of the lipid raft and tetraspanin web in MHC II K–deficient DCs and improves the ability of the 
DCs to engage and activate thymocytes and drive Treg cell differentiation. (A) BMDCs were derived from MHC IIK>R/K>R mice, treated with ethanol (EtOH) or 
sphingomyelin (SM; 200 µM) for 3 d and stained by using monoclonal antibodies raised against indicated molecules except that CTxB was used to detect 
GM1. (B–D) BMDCs derived from MHC IIK>R/K>R mice were treated with EtOH or SM and cultured with CD4+CD8− thymocytes isolated from OT-II mice in 
the presence of increasing concentrations of OVA323-339 peptide. The percentage of DCs that formed stable conjugates with thymocytes is shown in B. The 
percentage of thymocytes that expressed CD69 is shown in C. The level of CD25 expressed in CD69+ thymocytes is shown in D. (E and F) BMDCs derived 
from MHC IIK>R/K>R mice were treated with EtOH or SM and cultured with GFP−CD4+CD8− thymocytes isolated from Foxp3GFPOT-II mice in the presence of 
increasing concentrations of OVA323-339 peptide. 2 d later, the expression of GFP and CD25 in the thymocytes was determined by flow cytometry. Repre-
sentative dot plots are shown in E. The percentage of GFP+CD25+ cells among thymocytes (Treg cells) is shown in F. Data represent two to four independent 
experiments. Error bars represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.005.
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which the lipid raft and tetraspanin web were altered in thymic 
DCs. These data suggest the important contribution of the DC 
lipid raft and tetraspanin web to Treg cell development.
MAR CH1 significantly contributes to 
the diversification of Treg cell repertoire 
and function
Having found the mechanism by which MAR CH1 supports DC 
selection of Treg cells, we explored the functional significance 
of this mechanism. Specifically, we determined the contribu-
tion that MAR CH1 may make to the diversity of Treg cells. 
MAR CH1−/− mice were crossed to transgenic mice with a fixed 
TCRβ chain (Hsieh et al., 2004). Treg cells were isolated, and 
the variable TCRα chains were sequenced and analyzed at the 
individual TCR level (Fig. S5, A and B). We found a substan-
tial loss of Treg cell TCR clones in MAR CH1-deficient mice, 
estimated to comprise ∼33% of the Treg cell TCR clones 
present in WT mice (Fig.  9, A and B). Remarkably, most of 
them completely disappeared in MAR CH1−/− mice (Fig. 9 A). 
Some clones were found enriched, although the frequency was 
as low as 2.3% (Fig. 9, A and B). This finding indicates that 
MAR CH1 plays a significant role in diversifying Treg cell TCR 
repertoire. We also examined the TCR repertoire of non-Treg 
CD4+ thymocytes and found that 8.4% of the analyzed TCRs 
were enriched in MAR CH1−/− mice (Figs. S5, C and D). Thus, 
MAR CH1 appears to also play some role in negatively se-
lecting CD4+ thymocytes.
Next, we examined whether the restriction in the repertoire 
of Treg cells in MAR CH1-deficient mice is accompanied by the 
restriction in their functional capacity. Treg cells isolated from 
MAR CH1-deficient mice suppressed proliferation of CD4+ T 
cells as effectively as those from WT mice in vitro (Fig. 9 C). To 
assess Treg cell functionality in physiologically relevant settings, 
we used two in vivo assays. First, we transferred naive CD4+ T 
cells to lymphopenic mice (Powrie et al., 1994), which develop 
wasting disease and inflammatory bowel disease (IBD), which 
are ameliorated by cotransfer of Treg cells (Mottet et al., 2003). 
We found that Treg cells derived form MAR CH1-deficient mice 
suppressed both wasting disease and IBD as well as or more 
effectively than those from WT mice (Fig. 9 D and Fig. S5 E). 
Second, we used a mouse model of lethal acute graft-versus-host 
disease (aGVHD) preventable by cotransfer of Treg cells derived 
from the graft donor (Hoffmann et al., 2002). Transplantation of 
irradiated BALB/c mice with C57BL/6 mouse bone marrow cells 
that included CD4+ T cells but not Treg cells resulted in a precip-
itous death leaving no mice surviving on day 22 after transplan-
tation (Fig. 9 E). However, mice cotransplanted with Treg cells 
derived from WT C57BL/6 mice were substantially protected 
from death, resulting in about two thirds of the mice surviv-
ing over 36 d after transplantation (Fig. 9 E). In contrast, mice 
Figure 8. The degree of Treg cell deficiency in 
MAR CH1 or MHC II K–deficient mice correlates 
with the degree of alteration in the lipid raft 
and tetraspanin web in thymic DCs. (A) DCs 
were enriched from the thymic digest of WT, 
MHC IIK>R/K>R, and MHC IIK>R/- mice and stained 
by using monoclonal antibodies raised against 
indicated molecules except that CTxB was 
used to detect GM1. Sirpα− DCs are shown 
as the representative. Data represent at least 
three independent experiments. (B) WT (−) and 
Rip-mOVA (+) transgenic mice were lethally 
irradiated and transferred with bone marrow 
isolated from OT-II, MHC IIK>R/K>ROT-II, or MHC 
IIK>R/-OT-II mice. The percentage of OT-II Treg 
cells among CD4+ thymocytes was deter-
mined 6 wk later. (C) OT-II, MHC IIK>R/K>ROT-II, 
and MHC IIK>R/-OT-II mice were i.v.  injected 
with PBS (−) or 4 mg ovalbumin (+), and 
the percentage of OT-II Treg cells among 
CD4+ thymocytes was determined 3 d later. 
(D) The percentage of Treg cells among CD4+ 
thymocytes in WT, MHC IIK>R/K>R, and MHC 
IIK>R/- mice. (E) DCs were enriched from the 
thymic digest of WT, MAR CH1−/−, and MAR 
CH1−/+ mice and stained by using monoclonal 
antibodies raised against indicated molecules 
except that CTxB was used to detect GM1. 
Sirpα− DCs are shown as the representative. 
Data represent at least three independent ex-
periments. (F) Mice were treated as described in 
B, except that bone marrow was isolated from 
OT-II, MAR CH1−/−OT-II, and MAR CH1−/+OT-II 
mice. (G) Mice were treated as described in 
C, except that OT-II, MAR CH1−/−OT-II, and 
MAR CH1−/+OT-II mice were i.v.  injected with 
PBS (−) or ovalbumin (+). (H) The percentage 
of Treg cells among CD4+ thymocytes in WT, 
MAR CH1−/−, and MAR CH1−/+ mice. Each 
circle represents an individual mouse. Data 
were pooled from more than three indepen-
dent experiments. Error bars represent SEM. 
*, P < 0.05; **, P < 0.01.
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cotransplanted with Treg cells derived from MAR CH1-deficient 
C57BL/6 mice died as rapidly as those transplanted with CD4+ T 
cells alone, although some mice managed to live (Fig. 9 E). Thus, 
Treg cells generated in the absence of MAR CH1 are incompetent 
in suppressing lethal aGVHD. These findings suggest that MAR 
CH1 contributes to the diversification of the immunosuppressive 
function of Treg cells as well as TCR repertoire of the cells.
Discussion
The aim of this study was to define the mechanism by which 
MAR CH1-mediated ubiquitination of MHC II supports DC 
function of selecting natural Treg cells. The presented study 
indicates that ubiquitin-dependent MHC II turnover is required 
for DCs to maintain homeostasis of the lipid raft and tetraspanin 
web in the plasma membrane and that DC ability to engage and 
activate thymocytes is critically dependent on integrity of these 
membrane domains. Thus, MAR CH1-mediatd MHC II ubiquiti-
nation represents a novel quality-control mechanism by which 
DCs maintain homeostasis of membrane domains that supports 
Treg cell–selecting function.
Ubiquitination induces endocytosis and lysosomal sorting 
and degradation of MHC II. Accordingly, when the ubiquitin ac-
ceptor lysine of MHC II was mutated in mice, the level of MHC 
II molecules, including the antigen-loaded MHC II, markedly 
Figure 9. MAR CH1 significantly contributes to the diversification of Treg cell repertoire and function. (A) Dot plot of unique Treg cell TCR frequencies in 
MAR CH1−/− versus WT mice. Red and blue dots indicate unique TCRs significantly diminished and enriched in MAR CH1−/− mice, respectively (P < 0.075, 
Mann-Whitney U test). ND, not detected. (B) The percentages of unique Treg cell TCR clones diminished or enriched significantly and more than fivefold in 
MAR CH1−/− mice. (C) Treg cells were isolated from thymi of WT or MAR CH1−/− mice and mixed with CTV-labeled CD4+ T cells together with anti-CD3 and 
-CD28 antibody–coated beads. The percentages of CTV-diluted CD4+ T cells were determined. Data represent two independent experiments with triplicates 
per condition. Error bars represent SEM. (D and E) RAG1−/− mice were i.v. injected with naive WT CD4+ T cells alone or together with thymic Treg cells 
isolated from WT or MAR CH1−/− mice. The weight of individual mice was monitored and recorded for 56 d (D). Each curve represents the average weight 
changes of 12–13 mice per group. Histological scores of distal colons were determined as described in Materials and methods (E). Each circle represents 
an individual mouse. Data are pooled from three independent experiments. Error bars represent SEM. *, P < 0.05; **, P < 0.01. (F) BALB/c mice were 
lethally irradiated and i.v. injected with C57BL/6 mouse bone marrow cells depleted of whole T cells and supplemented with C57BL/6 mouse CD4+ T cells 
alone or together with thymic Treg cells isolated from WT or MAR CH1−/− mice. Survival of the mice was monitored for 36 d. Data were pooled from three 
independent experiments of 10–15 mice per group. Significance was tested by the log-rank test. *, P < 0.05.
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increased in DC surface. Yet, the DCs were less efficient at acti-
vating antigen-specific thymocytes than WT DCs. By using two 
independent methods, we showed that this reduced efficiency is 
attributed not to the absence of ubiquitinated MHC II molecules 
in the cells but to the presence of too many MHC II molecules. 
First, we found that the efficiency of MHC II K–deficient DCs 
at engaging and activating thymocytes was significantly im-
proved when the cells were manipulated to express only one 
allele of the MHC II. Second, DCs that expressed MHC II via an 
exogenous promoter that drove MHC II expression much more 
weakly compared with the endogenous promoter were able to 
stably engage and strongly activate thymocytes in the absence 
of the ubiquitin acceptor lysine in MHC II.
We found that MHC II K deficiency resulted in distortion 
of the lipid raft and tetraspanin web in the plasma membrane 
of DCs. This distortion was manifested by poor binding of the 
antibodies or ligands directed to GPI-anchored molecules, GM1, 
or tetraspanin molecules. This poor binding appears to be largely 
attributed to conformational changes of the individual molecules 
driven by MHC II overcrowding in the membrane domains. A 
recent study has shown that the fraction of GM1 molecules 
available for CTxB binding changes as the property of GM1- 
associating membrane changes (Sachl et al., 2015). Another re-
cent study has shown that tetraspanin molecules contain a large 
intramembrane cavity occupied by cholesterol and that the oc-
cupancy of this cavity modulates conformation of tetraspanins 
(Zimmerman et al., 2016). Possibly, the lipid raft and tetraspanin 
web in MHC II K–deficient DCs were altered in membrane prop-
erty by MHC II overcrowding, which resulted in conformational 
changes in the associated molecules including GM1. Nota-
bly, we found that the amount of CD24 present in MHC II K– 
deficient DCs was slightly lower than that in WT DCs, although 
the amount of CD24 transcript was identical. We speculate that 
some of the CD24 molecules in MHC II K–deficient DCs might 
have been cleaved from the cell surface because phosphatidy-
linositol-phospholipase C and the angiotensin-converting en-
zyme, the enzymes capable of cleaving GPI anchor, are activated 
upon destabilization of the lipid raft (Metz et al., 1994; Sharom 
and Lehto, 2002; Kondoh et al., 2005). Additional studies using 
high-resolution microscopy and biophysical experiments would 
help in understanding the molecular changes occurring in the 
plasma membrane of MHC II-overcrowded DCs.
The lipid raft and tetraspanin web both promote DC ac-
tivity of engaging and activating mature CD4+ T cells (Ander-
son et al., 2000; Kropshofer et al., 2002; Hiltbold et al., 2003). 
However, the role of these membrane domains in DC activity of 
engaging, activating, and differentiating CD4+ thymocytes has 
not been investigated. Cholesterol and sphingolipid both play 
an important role in maintaining structural integrity of the lipid 
raft as well as the tetraspanin web (Odintsova et al., 2006). We 
found that DCs treated with the reagents that reduce cellular 
levels of cholesterol or sphingolipid were poorly bound by the 
antibodies or ligand directed to the molecules associated with 
the lipid raft or tetraspanin web, similarly to what was found 
in MHC II K–deficient DCs. DCs treated with these reagents 
also poorly engaged and activated thymocytes compared with 
untreated DCs. This finding supports that the lipid raft and tet-
raspanin web were disrupted in MHC II K–deficient DCs and 
that these membrane domains play an important role in DCs to 
stably engage and strongly activate thymocytes.
The specific mechanisms by which the lipid raft or tetrasp-
anin web supports DC ability to conjugate and activate thymo-
cytes remain to be further defined. We found that pretreatment 
with anti-CD48 antibody resulted in a significant reduction in 
DC ability to engage and activate thymocytes, implicating a role 
of CD48. CD48 has been shown to bind the adhesion molecule 
CD2 and facilitate activation of T cells (Kato et al., 1992). A 
similar mechanism may explain the contribution of CD48 to 
DC engagement and activation of thymocytes. Pretreatment 
of DCs with anti-CD9 antibody also resulted in a reduction in 
DC engagement and activation of thymocytes, although only 
the KMC8 antibody but not the MZ3 antibody did so. Although 
the specific epitope recognized by the KMC8 antibody is not 
known, that epitope may mediate CD9 interaction with some 
other molecules that promote DC engagement and activation of 
thymocytes. CD9 and CD81 can interact with multiple integrin 
molecules in the plasma membrane through their ectodomains 
(Berditchevski, 2001). CD9 and CD81 are also connected 
to actin cytoskeleton involving ezrin-radixin-moesin proteins 
(Sala-Valdés et al., 2006). Thus, these tetraspanin molecules 
may serve as a linker between adhesion molecules on the sur-
face of DCs and the cytoskeleton in the cortex and promote 
stable DC interaction with thymocytes. The co-stimulatory 
molecule CD86 has been shown to be recruited to the lipid raft 
upon T cell–DC interaction, implicating the role of the lipid 
raft in T cell stimulatory activity of CD86. Although we did not 
examine it in this study, MHC II K deficiency may have caused 
CD86 to poorly associate with the lipid raft in MHC II (K>R) 
DCs making it unable to provide sufficient co-stimulatory sig-
nal to the interacting thymocytes.
We found that MAR CH1 deficiency reduced not only the 
number of Treg cells but also repertoire of the cells. Approx-
imately 33% of Treg TCR clones diminished in MAR CH1- 
deficient mice, and the majority of them were undetectable. We 
also found some clones of non-Treg CD4+ thymocytes were 
enriched in MAR CH1-deficient mice. However, the frequency 
of these enriched clones comprised only 8% of total non-Treg 
CD4+ thymocyte repertoire, implicating a relatively minor role of 
MAR CH1 in negative selection over Treg cell development. Both 
negative selection and Treg cell development are promoted by 
high-affinity interaction between DCs and thymocytes. However, 
a recent study has revealed that the TCR affinity threshold to 
elicit negative selection is ∼100-fold higher than that of Treg cell 
development. This study also showed that Treg cells can develop 
in a broad ∼1,000-fold range of TCR affinity. This extremely 
broad range of Treg cell affinity may be attributed to the role of 
the lipid raft and tetraspanin web in promoting DC engagement 
and activation of thymocytes. We found that the Treg cells gener-
ated in the absence of MAR CH1 sufficiently suppressed wasting 
disease and IBD but not aGVHD. Previous studies have shown 
that the alloantigen-specific Treg cells suppressed alloreactive 
effector T cells more effectively than polyclonal Treg cells in 
vitro (Chen et al., 2009; Veerapathran et al., 2013). Alloantigen- 
specific Treg cells also suppressed aGVHD more effectively than 
polyclonal Treg cells when transferred to mice that received al-
lotransplantation (Yamazaki et al., 2006; Golshayan et al., 2007). 
Thus, MAR CH1 may play a particularly important role in the 
development of Treg cells reactive to alloantigens.
In conclusion, this study reveals an unexpected role of 
MAR CH1 and MHC II ubiquitination in DC membrane ho-
meostasis and Treg cell–selecting function. The dependency 
of MAR CH1 and MHC II ubiquitination in other DC functions, 
such as development of effector T cells, would be an important 
remaining topic to be studied.
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Materials and methods
Mice
C57BL/6, BALB/c, B6.PL-Thy1a/CyJ (Thy1.1), B6.129S2-H2dlAb1-Ea/J 
(MHC II−/−), B6.129S2-Tcratm1Mom/J (TCRα−/−), B6.129S7-Rag1tm/1Mom/J 
(Rag1−/−), B6.Cg-Tg(Itgax-cre)1-1Reiz/J (CD11c-CRE), B6.Cg- 
Tg(UBC-cre/ERT2)1Ejb (ERT-CRE), B6;SJL-Tg(ACT FLPe)9205-
Dym/J (ACT-FLP), B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II), and 
B6.SJL-Ptprca Pepcb/BoyJ (BoyJ) mice were purchased from the Jack-
son Laboratory. B6.129-H20Ab1tm1GruN12 (MHC IIβ−/−) mice were 
purchased from Taconic. MHC IIK>R/K>R (Oh et al., 2013), MAR CH1−/− 
(Matsuki et al., 2007), Rip-mOVA (Kurts et al., 1996), foxp3GFP 
(Haribhai et al., 2007), and TCli β transgenic (Hsieh et al., 2004) mice 
were described previously. All mice were maintained in the University 
of California, San Francisco (UCSF), mouse facility, and all animal 
studies were performed according to protocols approved by the UCSF 
Institutional Animal Ethics Committee.
Antibodies and reagents
The following antibodies were purchased from BioLegend, eBioscience, 
or BD Biosciences and used for flow cytometry or enrichment: FITC-
Sirpα, PE/Cy7-Sirpα, PerCP/Cy5.5-B220, APC-EpCAM, PE-CD11c, PE/
Cy7-CD11c, Brilliant Violet 605-CD11c, Pacific Blue-IA/IE, FITC-CD8α, 
Alexa700-CD8α, PE-Vα2, APC-Vα2, APC-Vβ5, PE-Vβ6, PE-Foxp3, 
Pacific Blue-Foxp3, PerCP/Cy5.5-Thy1.1, APC-TCRβ, PE-CD69, PE/
Cy7-CD69, Brilliant Violet 605-CD4, APC-CD25, Brilliant Violet 605-
CD25, Brilliant Violet 785-CD25, FITC-CD45RB, APC-ICAM1, PR-
CD9, PE-CD81, APC-CD48, PE/Cy7-CD24, APC-CD24, PE-CD71, PE/
Cy7-CD45, APC-streptavidin, Biotin-Thy1.2, Biotin-CD8β, Biotin-CD25, 
and Biotin-B220. Alexa647-CTxB subunit was purchased from Molecular 
Probes. For Western blotting, the following clones were used: MHC II β 
chain (Bett; homemade), CD48 (OX-78; Serotec), CD24 (M1/69; BioLeg-
end), actin (A2066; Sigma), CD9 (LMC8; eBioscience), and CD81 (Eat2; 
BioLegend), and HRP-conjugated secondary antibodies (anti-rat, anti- 
rabbit, and anti-hamster) were purchased from Jackson ImmunoResearch 
or BIO SOU RCE. Myriocin, MβCD, cholesterol, sphingomyelin, and 4- 
hydroxy-tamoxifen were purchased from Sigma.
Generation of MAR CH1fl/flCD11c-CRE mice
Embryonic stem cells containing targeted conditional alleles of 
MAR CH1 were purchased from EUC OMM and transplanted to 
C57BL/6 mice in the UC Davis Mouse Biology Program. Two chi-
meric mice were generated, and both mice successfully provided 
germ-line transmission. One of them was crossed with Act-FLP trans-
genic mice to remove the FRT flanking region and subsequently with 
CD11c-CRE or ERT-Cre transgenic mice to remove the loxP-flank-
ing region. See Fig. S1.
Isolation of thymic DCs
Thymi were isolated and digested with 125 mg/ml collagenase D 
and 62.5 µg/ml DNaseI for 20 min with gentle rocking at 37°C. Di-
gests were filtered through a 70-µm filter cap strainer (BD Falcon), 
resuspended in 1  ml high-density (1.115  g/ml) Percoll solution (GE 
healthcare), and layered with 1  ml low-density (1.065  g/ml) Percoll 
solution followed by 1 ml PBS. This Percoll gradient was centrifuged 
at 2,700 rpm for 30 min at 4°C to enrich antigen-presenting cells. Cells 
between the PBS and low-density Percoll layer were isolated and used 
for flow cytometric analysis as described in our previous study (Oh et 
al., 2013) or enriched further by using magnetic beads conjugated with 
anti-CD11c antibody (Miltenyi Biotec).
Culture of BMDCs and isolation of conventional DCs (cDCs)
Bone marrow cells were cultured with RPMI media supplemented with 
10% FBS and 100 ng/ml Flt3-ligand (Peprotech) for 12 d. For isola-
tion of cDCs, cells were harvested and preincubated with Fc block for 
10 min on ice in MACS buffer (PBS with 1% BSA and 2 mM EDTA) 
and then with biotin-B220 antibody and streptavidin–magnetic bead 
to remove plasmacytoid DCs. These cDCs were further purified by 
cell sorting before RNA isolation, Western blotting, and sucrose 
gradient fractionation.
Retroviral transduction of BMDCs
The retrovirus encoding MHC II WT, MHC II (K>R) mutant, or CD86 
(K>R) mutant was generated as previously described (Shin et al., 2006; 
Baravalle et al., 2011). The generated virus was mixed with polybrene 
(10 µg/ml) and added to BMDCs on the second day of culture. The 
BMDCs were spun at 2,500 rpm for 2 h at RT, and the supernatant was 
replaced with the Flt3-ligand-containing media. Cells were cultured for 
an additional 10 to 12 d.
Quantitative PCR
Genomic DNA was purified using the PureLink genomic DNA 
Mini kit (Invitrogen) from Sirpα− DCs (CD11c+MHC II+B220− 
autofluorescence−Sirpα−), Sirpα+ DCs (CD11c+MHC II+B220− 
autofluorescence−Sirpα+), B cells (B220+MHC II+CD11c−), and 
thymic epithelial cells (EpCAM+MHC II+CD11c−B220−) isolated 
from the thymi of MAR CH1fl/fl and MAR CH1fl/fl CD11c-CRE mice. 
Quantitate PCR was performed on an Eppendorf realplex system by 
using SYBR Green reagents and the primer pair spanning 3′ LoxP site 
(5′ primer, AGC TGT AAG AAC TGA CCT CAA; 3′ primer, GGA GGA 
TGC TTG TCC TGT AAA). See also Fig. S1. Total RNAs were isolated 
from sorted cDCs by TRIzol (Invitrogen). The first-strand cDNA was 
generated by using SuperScript III system (Invitrogen) with the use of 
oligo dT as primer. Quantitative PCR was performed by using primers 
specific for CD48, CD24, Sptlc2, CD9, and HPRT (https ://pga .mgh 
.harvard .edu /primerbank /).
Flow cytometry and cell sorting
Cells were incubated with fluorophore-conjugated antibodies in FACS 
buffer (1% BSA in PBS) containing propidium iodide solution (Bio-
Legend) for 30 min on ice. When staining DCs, cells were preincubated 
with CD16/32 Fc block antibody (UCSF Cell Culture Facility). Foxp3 
was stained by using Foxp3/Transcription Factor Staining Buffer Set 
as instructed (eBioscience). Samples were analyzed and sorted by the 
FACS LSR II system (BD Biosciences) and BD FACS Aria3 Cell Sorter 
(BD Biosciences), respectively.
Thymocyte conjugation and activation assay
CD4+ thymocytes were isolated through negative selection by using 
biotin-CD8β and biotin-CD25 antibodies and streptavidin-conjugated 
magnetic beads (Stemcell Technologies) from Thy1.1 OT-II mice. 
Isolated cells (1 × 105) were co-cultured with thymic DCs (2 × 104) 
or BMDCs (2 × 104) in the presence of increasing amounts of OVA 
protein or OVA323-339 peptide. Thymocyte conjugation was assayed 
after 3 h by centrifuging cell mixtures and vortexing pellets for 5 s at 
the highest speed before fixation and antibody staining. The percent-
age of Thy1.1+Vβ5+ cells among CD11c+MHC II+ population was de-
termined by flow cytometry. Thymocyte activation was assayed after 
24 h by determining the percentages of CD69+ and the geometric mean 
fluorescence intensity of CD25 of CD69+ among Thy1.1+Vβ5+ popu-
lation by flow cytometry.
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Western blotting
cDCs isolated from WT and MHC IIK>R/K>R BMDCs were boiled in Lae-
mmli buffer for 5 min and run on SDS-PAGE. Gels were transferred to 
polyvinylidene difluoride membrane, and the membranes were prein-
cubated with blocking solution (5% nonfat milk in PBST [PBS with 
0.1% Tween-20]) with gentle agitation for at least 30 min, which was 
followed by primary antibody incubation for overnight at 4°C and sec-
ondary antibody incubation for 1 h at RT. ECL reaction was performed, 
and the membrane was imaged by using ChemiDoc XRS+ (Bio-Rad).
Sucrose gradient fractionation
BMDCs were lysed with MES-buffered saline (150  mM NaCl and 
25 mM Mes, pH 6.2) containing 1% Brij-58 (Surfact-Amps 58; Thermo 
Scientific) in the presence of Halt protease inhibitor Cocktail (Thermo 
Scientific). The lysates were adjusted to 40% sucrose and overlaid over 
a 35–5% sucrose gradient and centrifuged at 45,000 rpm for 18 h. 10 
equal fractions were collected from the top of the gradient and used 
for Western blot analyses.
Bone marrow transplantation
Bone marrow cells were isolated from femurs and/or tibiae of the 
donor mice. Recipient mice were lethally irradiated (1,200 rad) 
and intravenously injected with 3–5 × 106 bone marrow cells. Mice 
were examined 6 wk later.
Treg cell TCR repertoire sequencing
Treg cell and non-Treg CD4+ thymocyte TCR repertoire sequenc-
ing was performed as previously described (Perry et al., 2014). 
In brief, CD4+CD8−GFP+CD25+CD24−Vβ6+Vα2+ Treg cells and 
CD4+CD8−GFP−CD25−CD24−Vβ6+Vα2+ non-Treg CD4+ thymocytes 
were isolated from thymi of 5- to 6-wk-old TCliβ;foxp3-EGFP;TCRα−/+ 
mice and MAR CH1−/−;TCliβ;foxp3-EGFP;TCRα−/+ mice. cDNA was 
synthesized by using a TCRα specific primer (Perry et al., 2014) and 
used for amplification of the TRAV14 gene segment. The TRAV14 PCR 
proceeded in two steps; the first involved the TRAV14-specific primer 
(5′-GCA GCA GGT GAG ACA AAG-3′) and an extension sequence (5′-
ACA CGA CGC TCT TCC GAT CT-3′) with a Cα-specific reverse primer 
(5′-TCA GCA GGA GGA TTC GGA GTC CCA-3′). The second step used 
a nested PCR with a forward primer containing the MiSeq Universal 
Adapter sequence and a sequence complementary to the common exten-
sion sequence from PCR 1 with a reverse primer containing the Miseq 
Universal Adapter, an 8-bp hamming code, and a sequence comple-
mentary to a portion of the Cα-specific reverse primer. Resulting am-
plicons were sequenced via 250-bp paired-end reads by using a MiSeq 
sequencer (Illumina). Sequences were demultiplexed and analyzed using 
blastn to identify the TRAV and TRAJ gene segments by using the IMGT 
database (Giudicelli et al., 2006). Downstream analysis was performed 
as reported previously (Perry et al., 2014). See also Fig. S5 (A and B).
In vitro Treg cell suppression assay
CD25−CD4+CD8− conventional CD4+ T cells (2.5 × 104 cells) sorted 
from BoyJ (CD45.1+) mice spleens were labeled with Celltrace Vio-
let (CTV; Invitrogen) and mixed with Treg cells (CD25+CD4+CD8−) 
sorted from thymi of WT or MAR CH1−/− mice to various ratios. The 
cell mixtures were added with 104 beads conjugated with anti-CD3 and 
anti-CD28 antibodies and cultured in 37°C for 3 d. The percentages 
of CD45.1+ conventional CD4+ T cells with their CTV diluted were 
determined by flow cytometry.
Treg cell–dependent suppression of wasting disease and IBD
Naive CD4+ T cells (CD45RBhiCD25−CD4+CD8−) were isolated from 
WT mouse spleens and lymph nodes and injected into 9- to 12-wk-
old Rag1−/− mice (4–5 × 105 cells per mouse). Some mice were also 
injected with Treg cells isolated from WT or MAR CH1−/− mice thymi 
(2–2.5 × 105 cells per mouse). Mice were weighed every 2–3 d. Mice 
were euthanized on day 56, and distal colons were stained by using 
hematoxylin and eosin. The pathology was scored as follows: mu-
cosal damage (0, none; 1, discrete lymphoepithelial lesions; 2, dif-
fuse crypt elongation; or 3, extensive crypt elongation or mucosal 
ulceration), immune cell infiltration (0, none; 1, widely scattered leu-
kocytes or focal aggregates; 2, confluent leukocytes extending into 
submucosa with focal effacement of the mucosa; or 3, leukocyte in-
filtration with transmural extension), and crypt abscess (0, absent; or 
1, present; Yamaji et al., 2012). Values for each slide were summed 
for a total score of 0–7.
Treg cell–dependent suppression of lethal acute GVHD.
T cell–depleted C57BL/6 mouse bone marrow cells were mixed with 
conventional CD4+ T cells (CD25−CD4+CD8−) isolated from C57BL/6 
mouse spleens and lymph nodes. The cell mixtures were injected into 
lethally irradiated (850 rad) 8- to 10-wk-old BALB/c mice (2–3 × 106 
T cell–depleted bone marrow cells and 4–5 × 105 conventional CD4+ T 
cells per mouse). Some mice were also injected with Treg cells isolated 
from WT and MAR CH1−/− mice thymi (2–2.5 × 105 cells per mouse). 
Viability of mice was monitored every day for record.
Software and statistical analyses
Flow cytometry data were analyzed by FlowJo. Graphs were drawn by 
PRI SM (GraphPad). Unpaired two-tailed Student’s t test was performed 
to assess the significance unless stated otherwise. R v3.2.3 was used for 
graphical and statistical analysis of TCR repertoire data. The R package 
DESeq2 (v1.10.3) was used for differential TCR expression analysis, and 
vegan (v2.3-5) for dimensional analysis, rarefaction, and visualization.
Online supplemental material
Fig. S1 shows the map of the MAR CH1 exon6-targeting construct used 
to generate MAR CH1fl/fl mice. Fig. S2 shows the surface expression of 
MHC II, CD86, CD80, and ICAM1 in thymic DCs of WT, MAR CH1−/−, 
or MHC IIK>R/K>R mice. Fig. S3 shows the association of MHC II with 
the lipid raft in WT and MHC IIK>R/K>R DCs. Fig. S4 shows that the 
excessive accumulation of CD86 in DCs does not alter the lipid raft or 
tetraspanin web. Fig. S5 provides additional details related to the TCR 
repertoire analysis and representative images of colonic inflammation 
of the IBD mouse model.
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